Ian Churcher

Company: Amphista Therapeutics
Job title: CSO
Seminars:
New Approaches to Degradation – Beyond the Usual Suspects 9:00 am
Amphista Therapeutics uses a completely novel range of mechanisms to degrade a wide range of disease-relevant proteins Mechanisms go beyond the usual E3 ligases utilised by most in the field and instead use other UPS proteins which offer new opportunities to expand the scope and utility of TPD strategies We will discuss how novel mechanisms…Read more
day: Day One